About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

378040 studies
220 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/15/2021.
This website is for US healthcare professionals

Log In to Bolder Science


Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/15/2021.

Assessment of Natural Killer Cells in Unexplained Recurrent Pregnancy Loss

Clinicaltrials.gov identifier NCT03941470

Recruitment Status Active, not recruiting

First Posted May 8, 2019

Last update posted May 8, 2019

Study Description

Brief summary:

To assess natural killer cells frequency and activation in cases of unexplained recurrent abortion in comparison to fertile cases - 2. . To study the expression of stimulatory receptors of natural killer cell. - 3-To study the expression of inhibitory receptors of natural killer cell.

  • Condition or Disease:Recurrent Miscarriage
    Unexplained Pregnancy Loss
  • Intervention/Treatment:
  • Phase: N/A
Detailed Description

NK-cell functioning is controlled by a wide range of receptors that are expressed on the cell surface. These receptors are either inhibitory or activating in nature. The family of inhibitory receptors consists of the killer immunoglobulin-like receptors (KIR) or Ig-like receptors (CD158), the C type lectin receptors (CD94-NKG2A) and leukocyte inhibitory receptors (LIR1, LAIR-1). Activating receptors are the natural cytotoxic receptors (NKp46, NKp44), C type lectin receptors (NKG2D, CD94-NKG2C), and Ig-like receptors (2B4). A particular NK cell typically expresses two to four inhibitory receptors in addition to an array of activation receptors. The killing by NK cells is mediated through several activating NK receptors. Among these are NKG2D and the three natural cytotoxicity receptors (NCRs), NKp30, NKp44, and NKp46 (Yang et al., 2000) Osne of the natural cytotoxicity receptors (NCRs) NKp46, , is a unique marker that functions in NK cell cytotoxicity and cytokine production. Expression of NKp46 on NK cells is lower in women with recurrent pregnancy loss, so evaluation of NKp46 on peripheral blood NK cells may provide a means of screening for reproductive abnormalities (Fukui et al., 2015). During pregnancy, decidual NK cells comprise ∼70-80% of the decidual lymphocytes and are considered a special NK subset that does not exert cytolytic functions against trophoblast cells and has generally reduced cytotoxicity (Hanna and Mandelboim, 2007). These cells express activating NK receptors, including all the NCRs and NKG2D. However, instead of triggering cytotoxicity, these receptors act to stimulate secretion of cytokines and angiogenic factors, which are essential for trophoblast invasion and vascular modifications (Hanna et al., 2006). One study reported that pNK cell levels show changes in decidual NK cell levels (Park et al., 2010). Whereas some other reports have shown that the assessment of peripheral blood NK cells would not

Study Design
  • Study Type: Observational
  • Estimated Enrollment: 60 participants
  • Observational Model: Case-Control
  • Time Perspective: Other
  • Official Title: Assessment of Natural Killer Cells Activating and Inhibitors
  • Actual Study Start Date: April 2019
  • Estimated Primary Completion Date: December 2019
  • Estimated Study Completion Date: July 2020
Outcome Measures
  • Primary Outcome Measures: 1. asses the number of Natural killer cells [ Time Frame: 15 month ]
Eligibility Criteria
  • Ages Eligible for Study: up to 35 / (18 to 64 years)
  • Sexes Eligible for Study: Female
  • Accepts Healthy Volunteers: No
  • Sampling Method: Probability Sample
  • Study Population: We will recruit patients from outpatient clinics from Assuit University Hospital,Women fulfilling eligibility criteria will be included after careful gynecologycal examination,Those who consent to participate will be referred to the lab for investigation.

Inclusion Criteria:

- 1.Age less than 40 years. 2.History of two or more spontaneous miscarriages .

Exclusion Criteria:

- 1. Age more than 35 years. 2. Women with elevated level of TSH above (2.5 mIU/ml) or
prolactin above( 19.5 ng/mL)and uncontrolled DM.

3. Women with autoimmune disorder (antiphospholipid antibody syndrome)with LA1/LA2
ratio more than( 1.2).

4.Women receiving oral contraceptive pills.

Contacts and Locations

Yossra Mahmoud Mohammed

Sponsors and Collaborators

Assiut University


Principal Investigator: assiut university Assiut University

More Information